LFCR
Price
$7.87
Change
-$0.11 (-1.38%)
Updated
Feb 4, 02:55 PM (EDT)
Capitalization
298.79M
Intraday BUY SELL Signals
PBH
Price
$66.70
Change
+$2.28 (+3.54%)
Updated
Feb 4, 03:08 PM (EDT)
Capitalization
3.1B
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LFCR vs PBH

Header iconLFCR vs PBH Comparison
Open Charts LFCR vs PBHBanner chart's image
Lifecore Biomedical
Price$7.87
Change-$0.11 (-1.38%)
Volume$117
Capitalization298.79M
Prestige Consumer Healthcare
Price$66.70
Change+$2.28 (+3.54%)
Volume$1.04K
Capitalization3.1B
LFCR vs PBH Comparison Chart in %
LFCR
Daily Signal:
Gain/Loss:
PBH
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
LFCR vs. PBH commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LFCR is a Hold and PBH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (LFCR: $7.97 vs. PBH: $64.43)
Brand notoriety: LFCR and PBH are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: LFCR: 93% vs. PBH: 126%
Market capitalization -- LFCR: $298.79M vs. PBH: $3.1B
LFCR [@Pharmaceuticals: Generic] is valued at $298.79M. PBH’s [@Pharmaceuticals: Generic] market capitalization is $3.1B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.79B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LFCR’s FA Score shows that 1 FA rating(s) are green whilePBH’s FA Score has 0 green FA rating(s).

  • LFCR’s FA Score: 1 green, 4 red.
  • PBH’s FA Score: 0 green, 5 red.
According to our system of comparison, LFCR is a better buy in the long-term than PBH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LFCR’s TA Score shows that 1 TA indicator(s) are bullish while PBH’s TA Score has 3 bullish TA indicator(s).

  • LFCR’s TA Score: 1 bullish, 8 bearish.
  • PBH’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, PBH is a better buy in the short-term than LFCR.

Price Growth

LFCR (@Pharmaceuticals: Generic) experienced а -8.07% price change this week, while PBH (@Pharmaceuticals: Generic) price change was +0.83% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.83%. For the same industry, the average monthly price growth was -2.35%, and the average quarterly price growth was +12.98%.

Reported Earning Dates

PBH is expected to report earnings on Feb 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.83% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PBH($3.1B) has a higher market cap than LFCR($299M). LFCR has higher P/E ratio than PBH: LFCR (51.23) vs PBH (15.95). PBH YTD gains are higher at: 4.442 vs. LFCR (-2.567). PBH has higher annual earnings (EBITDA): 357M vs. LFCR (-8.81M). PBH has more cash in the bank: 119M vs. LFCR (18.9M). LFCR has less debt than PBH: LFCR (136M) vs PBH (1.04B). PBH has higher revenues than LFCR: PBH (1.11B) vs LFCR (129M).
LFCRPBHLFCR / PBH
Capitalization299M3.1B10%
EBITDA-8.81M357M-2%
Gain YTD-2.5674.442-58%
P/E Ratio51.2315.95321%
Revenue129M1.11B12%
Total Cash18.9M119M16%
Total Debt136M1.04B13%
FUNDAMENTALS RATINGS
LFCR vs PBH: Fundamental Ratings
LFCR
PBH
OUTLOOK RATING
1..100
283
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
10053
SMR RATING
1..100
10066
PRICE GROWTH RATING
1..100
4457
P/E GROWTH RATING
1..100
566
SEASONALITY SCORE
1..100
6550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBH's Valuation (85) in the Pharmaceuticals Other industry is in the same range as LFCR (95) in the Industrial Specialties industry. This means that PBH’s stock grew similarly to LFCR’s over the last 12 months.

PBH's Profit vs Risk Rating (53) in the Pharmaceuticals Other industry is somewhat better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that PBH’s stock grew somewhat faster than LFCR’s over the last 12 months.

PBH's SMR Rating (66) in the Pharmaceuticals Other industry is somewhat better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that PBH’s stock grew somewhat faster than LFCR’s over the last 12 months.

LFCR's Price Growth Rating (44) in the Industrial Specialties industry is in the same range as PBH (57) in the Pharmaceuticals Other industry. This means that LFCR’s stock grew similarly to PBH’s over the last 12 months.

LFCR's P/E Growth Rating (5) in the Industrial Specialties industry is somewhat better than the same rating for PBH (66) in the Pharmaceuticals Other industry. This means that LFCR’s stock grew somewhat faster than PBH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LFCRPBH
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
47%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
58%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
53%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
66%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
53%
Advances
ODDS (%)
Bullish Trend 14 days ago
77%
Bullish Trend 3 days ago
55%
Declines
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 8 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
67%
Aroon
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
51%
View a ticker or compare two or three
Interact to see
Advertisement
LFCR
Daily Signal:
Gain/Loss:
PBH
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRESX11.530.04
+0.35%
Cromwell CenterSquare Real Estate Inv
HWLIX45.93-0.02
-0.04%
Hotchkis & Wiley Large Cap Fdml Value I
PABCX18.78-0.06
-0.32%
PGIM Balanced C
AFDCX44.31-0.54
-1.20%
American Century Large Cap Equity C
AULGX99.21-1.86
-1.84%
American Century Ultra® R5

LFCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LFCR has been loosely correlated with AMRX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LFCR jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
-6.46%
AMRX - LFCR
37%
Loosely correlated
+0.42%
NBIX - LFCR
36%
Loosely correlated
+0.98%
SHPH - LFCR
31%
Poorly correlated
+2.79%
VTRS - LFCR
30%
Poorly correlated
N/A
ALKS - LFCR
30%
Poorly correlated
-1.40%
More

PBH and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBH has been loosely correlated with PAHC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PBH jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBH
1D Price
Change %
PBH100%
-1.54%
PAHC - PBH
38%
Loosely correlated
-1.43%
IRWD - PBH
32%
Poorly correlated
-3.04%
LFCR - PBH
30%
Poorly correlated
-6.46%
ELAN - PBH
29%
Poorly correlated
-1.62%
AMRX - PBH
29%
Poorly correlated
+0.42%
More